Bicara Therapeutics Inc. Common Stock
BCAXBicara Therapeutics Inc. (BCAX) is a biotechnology company focused on developing innovative immuno-oncology therapies. The company specializes in creating targeted treatments that modulate the immune system to combat cancer, leveraging its proprietary platform to develop novel antibody-based therapies.
Company News
Bicara Therapeutics CEO Claire Mazumdar sold 15,000 shares worth approximately $301,000 on May 18, 2026, through a pre-arranged Rule 10b5-1 trading plan adopted in February 2025. The sale reduced her direct holdings by 4%, but she retains 362,152 shares and 146,107 options, indicating continued substantial alignment with the company. The transact...
Bicara Therapeutics (NASDAQ: BCAX) successfully closed an oversubscribed public offering, raising approximately $172.5 million in gross proceeds through the sale of 8,581,250 common shares and 2,200,000 pre-funded warrants. The underwriters fully exercised their option to purchase additional shares. The company plans to use the proceeds to advanc...
Bicara Therapeutics priced a $150 million underwritten public offering of 7.175 million common shares at $16.00 per share and 2.2 million pre-funded warrants. The company plans to use proceeds to advance its lead candidate ficerafusp alfa, build commercial infrastructure, accelerate development in head and neck cancer, and fund manufacturing and ...
Bicara Therapeutics (NASDAQ: BCAX), a clinical-stage biopharmaceutical company, announced a proposed underwritten public offering of $150 million in common stock with a 30-day option for underwriters to purchase an additional $22.5 million. The company plans to use proceeds to advance its lead drug ficerafusp alfa, build commercial infrastructure...
Bicara Therapeutics will present at the J.P. Morgan 2026 Healthcare Conference, highlighting its lead program ficerafusp alfa, a bifunctional antibody designed to treat solid tumor cancers by targeting EGFR and TGF-β.
